Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

Recent findings indicate that widely used weight-loss medications might lead to muscle loss, including vital heart muscle, ...

Adults with obesity receiving once-weekly semaglutide 7.2 mg lost a higher proportion of their body weight at 72 weeks than ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Semaglutide, a weekly GLP-1 drug, caused weight loss of up to 13.9% after 68 weeks. Liraglutide, a daily GLP-1 drug, brought weight loss of up to 5.8% after 26 weeks. A pill form of semaglutide ...

Telehealth provider will make its big game debut as the semaglutide shortage continues to sustain the firm’s lower-priced ...

Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

The race is on for new drugs that suppress appetite, improve glucose regulation and can replace injections. But do they ...

Novo Nordisk (NVO) announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a ...

Weight loss pills are taken orally and (in most cases ... well-known GLP-1 that’s sometimes prescribed for weight loss is semaglutide, which is sold under the brand names Wegovy® and Ozempic®.